A-Z of Chemotherapy Drugs & Cancer Medicine Terms

 

Actinomycin D

Actinomycin D, also known as Dactinomycin, is one of the most commonly used chemotherapy drugs in Wilms tumor treatment. The medication works by interfering with cancer cell DNA, preventing tumor cells from growing and dividing. Actinomycin D is frequently combined with vincristine and other chemotherapy agents as part of standard treatment protocols for childhood kidney cancer. The drug has played a significant role in improving survival rates for children diagnosed with favorable histology Wilms tumor.

 

Anthracyclines

Anthracyclines are a class of chemotherapy drugs that includes medications such as doxorubicin. These drugs work by damaging cancer cell DNA and preventing tumor growth. Anthracyclines are often used in higher-stage or higher-risk Wilms tumor treatment protocols. While highly effective, they can be associated with long-term heart-related side effects, making cardiac monitoring an important part of treatment and survivorship care.

 

Busulfan

Busulfan is a chemotherapy drug sometimes used as part of high-dose treatment regimens prior to stem cell transplantation. It works by damaging cancer cell DNA and preventing cell replication. Busulfan is not commonly used in frontline Wilms tumor treatment but may be included in certain relapse or high-risk treatment protocols. Careful monitoring is required because high-dose therapy can affect multiple organ systems.

 

Carboplatin

Carboplatin is a platinum-based chemotherapy drug that may be used in relapsed or high-risk Wilms tumor treatment. The medication works by interfering with cancer cell DNA, making it difficult for tumor cells to survive and reproduce. Carboplatin is generally considered less toxic to the kidneys than cisplatin but may still cause side effects such as low blood counts, nausea, fatigue, and increased infection risk.

 

Chemotherapy

Chemotherapy is the use of anti-cancer drugs to destroy cancer cells and prevent tumor growth. It forms a cornerstone of modern Wilms tumor treatment and is often used before surgery, after surgery, or both, depending on the treatment protocol. Chemotherapy can eliminate microscopic disease, shrink tumors, reduce recurrence risk, and improve survival outcomes. Most children with Wilms tumor receive chemotherapy as part of their treatment plan.

 

Chemotherapy Cycle

A chemotherapy cycle refers to a planned period of treatment followed by a recovery period that allows the body to heal before the next dose is administered. Wilms tumor treatment typically involves multiple chemotherapy cycles delivered over several weeks or months. The number and duration of cycles depend on the tumor stage, histology, treatment protocol, and individual response to therapy.

 

Chemotherapy Protocol

A chemotherapy protocol is a standardized treatment plan that outlines which drugs are used, the doses administered, the treatment schedule, and the overall duration of therapy. Protocols are developed through extensive clinical research and help ensure that children receive evidence-based care. Treatment protocols vary depending on factors such as tumor stage, histology, and risk classification.

 

Cisplatin

Cisplatin is a platinum-based chemotherapy drug used in some high-risk and relapsed Wilms tumor treatment regimens. The drug works by damaging DNA within cancer cells, leading to cell death. Although highly effective, cisplatin may cause side effects including hearing loss, kidney toxicity, nausea, and nerve damage. Long-term follow-up is often recommended for children who receive cisplatin-based therapy.

 

Combination Chemotherapy

Combination chemotherapy refers to the use of multiple chemotherapy drugs together to improve treatment effectiveness. Combining medications that work through different mechanisms can increase cancer cell destruction while reducing the likelihood of drug resistance. Most Wilms tumor treatment protocols use combination chemotherapy approaches that have been shown to significantly improve survival outcomes.

 

Cyclophosphamide

Cyclophosphamide is a chemotherapy drug used in selected Wilms tumor treatment protocols, particularly for relapsed or higher-risk disease. It works by damaging cancer cell DNA and preventing cell division. Cyclophosphamide can be highly effective but may also increase the risk of side effects such as infection, infertility, bladder irritation, and reduced blood cell production.

 

Dactinomycin

Dactinomycin is one of the core chemotherapy drugs used to treat Wilms tumor. It interferes with cancer cell growth and replication by binding to DNA. Dactinomycin is frequently combined with vincristine and other medications and has contributed significantly to the excellent survival rates achieved in modern pediatric oncology. The drug remains a standard component of many frontline Wilms tumor treatment protocols.

 

Doxorubicin

Doxorubicin is an anthracycline chemotherapy drug commonly used in stage 3, stage 4, and higher-risk Wilms tumor treatment plans. It works by damaging cancer cell DNA and preventing tumor growth. Doxorubicin has significantly improved outcomes for children with advanced disease but may affect heart function over time. Survivorship programs often include long-term cardiac monitoring for children who received doxorubicin therapy.

 

Etoposide

Etoposide is a chemotherapy drug that interferes with the ability of cancer cells to repair damaged DNA. It is often used in combination with other chemotherapy agents in relapsed or high-risk Wilms tumor treatment protocols. Etoposide has become an important component of salvage therapy regimens and may be used alongside drugs such as carboplatin, cyclophosphamide, or ifosfamide.

 

High-Dose Chemotherapy

High-dose chemotherapy involves administering larger-than-standard doses of anti-cancer drugs to maximize cancer cell destruction. Because these treatments can severely affect bone marrow function, they are often combined with stem cell transplantation. High-dose chemotherapy may be considered for selected cases of relapsed or high-risk Wilms tumor where standard treatment approaches have not achieved the desired outcome.

 

Ifosfamide

Ifosfamide is a chemotherapy drug commonly used in relapse treatment and high-risk Wilms tumor protocols. Similar to cyclophosphamide, it works by damaging cancer cell DNA and preventing cell division. Ifosfamide may be highly effective against recurrent disease but requires careful monitoring because it can affect kidney function, bladder health, and blood cell production.

 

Irinotecan

Irinotecan is a chemotherapy drug that interferes with DNA replication and prevents cancer cells from dividing successfully. Although not routinely used in standard frontline Wilms tumor treatment, irinotecan may be considered in selected relapsed or refractory cases. Ongoing research continues to evaluate its role in pediatric oncology and childhood kidney cancer management.

 

Melphalan

Melphalan is a chemotherapy drug sometimes included in high-dose treatment regimens used before stem cell transplantation. It damages DNA within cancer cells and is primarily used in selected relapse settings. Melphalan may contribute to long-term remission in some patients but requires intensive supportive care due to its effects on bone marrow function.

 

Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy refers to chemotherapy administered before surgery. This approach is commonly used within SIOP treatment protocols and aims to shrink the tumor before surgical removal. Benefits may include reduced risk of tumor rupture, improved surgical outcomes, and increased opportunities for kidney-preserving surgery in selected cases.

 

Platinum-Based Chemotherapy

Platinum-based chemotherapy refers to drugs such as cisplatin and carboplatin that work by damaging cancer cell DNA. These medications are frequently used in relapsed or high-risk Wilms tumor treatment regimens and are valued for their ability to target aggressive cancer cells. Long-term monitoring is important because platinum-based therapies may affect hearing, kidney function, and nerve health.

 

Salvage Chemotherapy

Salvage chemotherapy is treatment administered after cancer has relapsed or failed to respond adequately to standard therapy. These regimens often use different combinations of drugs than those employed during initial treatment. Salvage chemotherapy may be combined with surgery, radiation therapy, stem cell transplantation, or clinical trial participation to improve outcomes in recurrent Wilms tumor.

 

Thiotepa

Thiotepa is a chemotherapy drug sometimes used in intensive treatment regimens for relapsed childhood cancers. It works by interfering with DNA function and preventing cancer cell reproduction. Thiotepa is most commonly associated with high-dose chemotherapy protocols and stem cell transplant preparation rather than frontline Wilms tumor therapy.

 

Topotecan

Topotecan is a chemotherapy drug that blocks enzymes needed for DNA replication and repair. It may be used in certain relapsed or refractory Wilms tumor treatment plans and is often combined with other chemotherapy agents. Research continues to evaluate the effectiveness of topotecan in improving outcomes for children with recurrent disease.

 

Vincristine

Vincristine is one of the most widely used chemotherapy drugs in Wilms tumor treatment and forms a cornerstone of many standard treatment protocols. The medication works by disrupting cancer cell division, preventing tumor growth and spread. Vincristine is commonly administered alongside dactinomycin and other chemotherapy agents and has contributed significantly to the remarkable improvements in childhood kidney cancer survival achieved over recent decades.

 

Vincristine-Dactinomycin Regimen

The Vincristine-Dactinomycin Regimen is one of the most frequently used chemotherapy combinations for favorable histology Wilms tumor. The two drugs work through different mechanisms to destroy cancer cells and reduce the risk of recurrence. This regimen has been a key component of successful treatment strategies and remains an important part of modern pediatric oncology care.

 

Vincristine-Dactinomycin-Doxorubicin Regimen

The Vincristine-Dactinomycin-Doxorubicin Regimen is commonly used for children with more advanced or higher-risk Wilms tumor. By combining three effective chemotherapy drugs, the regimen provides greater anti-cancer activity and improves outcomes for children with stage 3, stage 4, or certain high-risk forms of disease. Careful monitoring is required to manage potential side effects and long-term complications.